Bioponic Phytoceuticals Launches Curemisinin for the Treatment of Malaria in Guinea, Africa

Tuesday, November 13, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

MAUI, Hawaii, Nov. 13 Bioponic Phytoceuticals,Inc. (Pink Sheets: BPYT) ("Bioponic"), an innovative provider of naturalproducts and patented technology serving the Complementary AlternativeMedicine (CAM) and nutraceutical markets, announced today the launch ofCuremisinin(TM), an all-natural anti-malaria product that is based on threeproven effective anti-malaria herbs: Artemesia, Turmeric and Cinchona Bark,uniquely extracted through the Company's proprietary extraction/distillationtechnologies. This binary product comprises a nasal spray (Curemisinin A) withan oral spray (Curemisinin B) to treat malaria in the quickest, most effectivemanner.

Malaria is a disease caused by a blood parasite transmitted by mosquitoes,and the number one killer in sub-Saharan Africa, killing more than a millionpeople worldwide, every year. The majority of those who die from malaria areAfrican children, according to the Centers for Disease Control. ThroughBioponic's international alliance with Hyperdynamics Corp, Curemisinin iscurrently being disseminated free-of-charge in clinics located in the capitalcity of Guinea, Africa. The efficacy of Bioponic's Curemisinin will berecorded, and provide valuable data over the next several weeks on theproduct's ability to treat malaria in humans.

Bioponic's Chairman and CEO Steven M. Schorr remarked, "Curemisinin's useof a nasal delivery system allows the bioresonant liquid remedy to bedelivered directly to the brain via the nasal membrane. This may have asignificant impact on Cerebral Malaria, a condition primarily affectingchildren, who die within 24 to 72 hours without treatment. Bioponic not onlyhopes to stop the track of cerebral malaria, but potentially help bring downthe cost of treatment and increase the efficacy of treatments for all types ofmalaria, especially resistant strains of the disease."

As evolving pathogens develop widespread resistance to over-prescribedantibiotics, antivirals and antimalarial drugs, the use of natural medicinesis being recommended for their proven efficacy, even by the World HealthOrganization, who has indicated the benefits of artemisinin-based combinationtherapies (ACTs) as the front line of treatment for the vast malaria problem.For more information on Bioponic and Curemisinin, visit

About Bioponic Phytoceuticals

Bioponic Phytoceuticals is engaged in the development, production anddistribution of Bioresonant Phytotherapeutic(TM) products. The Company hasdeveloped several branded product lines, including the nasal spray: FlightSpray(R) (; Curecumin(TM) (a treatment forAlzheimer's Disease); O-Spray(TM) (scented nasal sprays); Throat Note(TM)(formulated for professional speakers and singers, great for everyone!) andthe effective natural skincare product Hawaiian Healing Mist(TM). Bioponic isfocused on the production of natural products that are used to promote healthand well-being.

All statements other than statements of historical fact included in thispress release are "forward-looking statements" within the meaning of federalsecurities laws. Such forward-looking statements are subject to a number ofrisks and uncertainties, some of which are beyond the Company's control.

CONTACT: Steven M. Schorr, CEO, Bioponic Phytoceuticals, +1-808-876-1711, or Geoffrey Eiten, Investor Relations, OTC FinancialNetwork, 781-444-6100x613,,

SOURCE Bioponic Phytoceuticals, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store